MINNEAPOLIS, MN, US, June 28, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, will provide an update regarding the MWI Distribution Services Agreement and discuss financial results for the year ended March 31, 2022, on Wednesday, June 29, 2022 at 4:00 p.m. CT (5:00 p.m. ET).
Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=4247f378-9329-46f0-adcf-44720e7f5ae6
A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below.
Date: Wednesday, June 29, 2022
Time: 4:00 p.m. CT (5:00 p.m. ET)
Dial-in number: +1 (346) 248-7799
Conference ID: 97245185036
Passcode: 740720
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV and PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of dogs and horses in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™, a veterinarian-administered, intraarticular injection for the management of osteoarthritis in dogs and horses, was made available for commercial sale in September, 2021.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
